Allopurinol: Novel indications in cardiovascular disease

Heart

Volumn 98, Issue 21, 2012, Pages 1543-1545

  Struthers, Allan ^a   Shearer, Fiona ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALLOPURINOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXANTHINE; OXYGEN; SUPEROXIDE; TROPONIN; URIC ACID; XANTHINE OXIDASE;

ACUTE CORONARY SYNDROME; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG INDICATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GOUT; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; LOW DRUG DOSE; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSIENT ISCHEMIC ATTACK;

ALLOPURINOL; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; OXIDATIVE STRESS;

EID: 84867915529     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302249     Document Type: Editorial

References (17)

1. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508-16. (Pubitemid 44901524)
2. Rajendra NS, Ireland S, George J, et al . Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 2011;58:820-8.
3. Rajagopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-9. (Pubitemid 26415078)
4. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241-8. (Pubitemid 46142995)
5. Khatib SY, Farah H, El-Migdadi F. Allopurinol enhances adenine nucleotide levels and improves myocardial function in isolated hypoxic rat heart. Biochemistry (Mosc) 2001;66:328-33. (Pubitemid 32445803)
6. Hirsch GA, Bottomley PA, Gerstenblith G, et al. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol 2012;59:802-8.
7. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999;85:437-45. (Pubitemid 29409620)
8. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-11. (Pubitemid 33108372)
9. Noman A, Ang DS, Ogston S, et al. Effect of high dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled, crossover trial. Lancet 2010;375:2161-7.
10. Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a Systematic review and Meta-Analysis. Cardiovasc Ther. Published Online First: 12 June 2011. doi:10.1111/j.1755-5922. 2011.00277.x
11. Rentoukas E, Tsarouhas K, Tsitsimpikou C, et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 2010;145:257-8.
12. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008;51:2301-9. (Pubitemid 351783365)
13. George J, Struthers A. The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. J Am Coll Cardiol 2009;53:2405.
14. Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011;22:1382-9.
15. Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 2009;48:804-6.
16. Thanassoulis G, Brophy JM, Richard H, et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170:1358-64.
17. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93.